May 6, 2014 / 10:15 AM / 3 years ago

AstraZeneca, fighting off Pfizer, forecasts $45 bln sales by 2023

LONDON, May 6 (Reuters) - AstraZeneca Plc, fighting off a $106 billion takeover approach from Pfizer Inc, painted a bullish picture of its new drug pipeline on Tuesday and forecast drug sales would exceed $45 billion by 2023.

Britain’s second biggest drugmaker recorded sales of $25.7 billion in 2013.

Reporting by Ben Hirschler; editing by Tom Bergin

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below